Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
Rhea-AI Summary
Priovant Therapeutics (NASDAQ:ROIV) announced FDA acceptance of its NDA for brepocitinib in dermatomyositis with Priority Review and a PDUFA target action date in Q3 2026. The company expects a U.S. launch at the end of September 2026 if approved.
Priority Review was supported by positive Phase 3 VALOR results (N=241), described as the first positive 52-week placebo-controlled trial in dermatomyositis; approval would represent the first targeted therapy for the disease.
Positive
- FDA Priority Review granted with PDUFA target in Q3 2026
- Phase 3 VALOR positive: longest, largest 52-week placebo-controlled DM trial (N=241)
- Potential first targeted therapy for dermatomyositis if approved
- Company expects U.S. launch end-September 2026 upon approval
Negative
- Approval is not guaranteed despite Priority Review and a PDUFA date
- Regulatory review could delay the planned end-September 2026 launch
- Clinical evidence centers on a single Phase 3 program (VALOR, N=241)
News Market Reaction – ROIV
On the day this news was published, ROIV declined 0.89%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.5% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $191M from the company's valuation, bringing the market cap to $21.26B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ROIV fell -2.9% while key biotech peers like MDGL, MRNA, HALO, VRNA, and BPMC showed positive moves, indicating stock-specific pressure despite positive regulatory news.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 06 | Positive Phase 2 data | Positive | +22.1% | Brepocitinib Phase 2 BEACON trial in cutaneous sarcoidosis showed strong efficacy. |
| Sep 17 | Phase 3 VALOR success | Positive | +7.8% | Phase 3 VALOR trial in dermatomyositis met endpoints with steroid-sparing benefits. |
| Dec 03 | Namilumab trial failure | Negative | -2.9% | Phase 2 RESOLVE-Lung study of namilumab in sarcoidosis failed all endpoints. |
| Dec 03 | Roivant on RESOLVE-Lung | Negative | -2.9% | Roivant detailed failed RESOLVE-Lung trial and discontinuation of namilumab program. |
| Sep 10 | Mosliciguat proof-of-concept | Positive | -2.5% | Positive Phase 1b ATMOS data for inhaled Mosliciguat in pulmonary hypertension. |
Clinical readouts often moved ROIV, with most clinical trial headlines aligning with the stock’s direction; positive brepocitinib data previously saw strong upside, while mixed pipeline results produced smaller, often negative moves.
Over the past two years, Roivant and its subsidiaries have delivered multiple key clinical milestones. Positive brepocitinib data in dermatomyositis and cutaneous sarcoidosis drove strong gains of up to 22.14%, underscoring investor focus on this asset. Other trial updates, including successes in pulmonary hypertension and failures in sarcoidosis, produced more modest reactions around -2.5% to -2.9%. Today’s FDA acceptance and Priority Review for brepocitinib in dermatomyositis builds directly on the Phase 3 VALOR results and the previously signaled NDA timeline.
Historical Comparison
Clinical-trial headlines for ROIV have averaged a 4.33% move, with larger swings around key brepocitinib readouts, framing today’s NDA acceptance as part of a longer clinical momentum arc.
The brepocitinib program progressed from positive Phase 3 VALOR dermatomyositis data and a planned NDA to today’s FDA NDA acceptance and Priority Review for dermatomyositis.
Regulatory & Risk Context
Roivant has an effective S-3ASR base shelf dated October 3, 2025, permitting issuance of common shares up to $400.0 million under a Sales Agreement; as of that filing, $0 had been sold.
Market Pulse Summary
This announcement confirms that the FDA has accepted Priovant’s NDA for brepocitinib in dermatomyositis and granted Priority Review with a PDUFA target in Q3 2026 and a planned US launch by the end of September 2026. It builds on prior positive Phase 3 VALOR data in dermatomyositis. Investors may track future FDA communications, commercialization plans around launch timing, and any additional brepocitinib readouts that could affect the overall risk–benefit profile.
Key Terms
pdufa regulatory
new drug application regulatory
priority review regulatory
phase 3 medical
placebo-controlled medical
dermatomyositis medical
AI-generated analysis. Not financial advice.
- FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026
- Priority Review supported by positive Phase 3 VALOR results, the first positive 52-week placebo-controlled trial in dermatomyositis
- If approved, brepocitinib would represent the first targeted therapy approved for dermatomyositis
DURHAM, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of calendar year 2026. The company expects to launch the drug in the United States at the end of September 2026.
The FDA grants Priority Review to applications for medicines that, if approved, provide significant improvements in the safety or effectiveness of the treatment of a serious condition. The Priority Review designation was supported by the significant unmet medical need in dermatomyositis and the results from the Phase 3 VALOR study evaluating brepocitinib in DM. VALOR (N=241) was the longest and largest interventional dermatomyositis trial to date and the first-ever positive 52-week placebo-controlled study in DM.
“The dermatomyositis patient and medical communities have been waiting for decades for novel innovative therapeutics that directly target the underlying disease biology, and it is incredibly exciting to have the finish line in sight for the potential first FDA approval of a targeted therapy for this debilitating disease,” said Dr. Ruth Ann Vleugels, M.D., M.P.H., M.B.A., Heidi and Scott C. Schuster Distinguished Chair in Dermatology, Founding Director of the Autoimmune Skin Disease Center and Connective Tissue Disease Clinics at Mass General Brigham and Program Director of the Dermatology-Rheumatology Fellowship at Harvard Medical School. “Dermatomyositis patients are suffering and urgently need better treatment options. The brepocitinib Phase 3 data suggests that this therapy has the potential to meaningfully improve these patients’ quality of life and function with a once-daily oral therapy. I am thrilled regarding this major step forward in our ability to care for our patients with dermatomyositis."
DM patients experience significant disease burden from muscle disease, skin disease, and frequent dependency on chronic high-dose steroids. Accumulated organ damage from uncontrolled chronic inflammation and the burdens of chronic steroid dependency contribute to high rates of comorbidities among DM patients on current standard of care.
“The acceptance of our NDA for brepocitinib in dermatomyositis represents meaningful progress towards our goal of bringing a potentially transformational therapy to dermatomyositis patients who urgently need better treatment options,” said Ben Zimmer, CEO of Priovant. “We are committed to working closely with the FDA through their review to make this drug available for patients as quickly as possible.”
About the Phase 3 VALOR Study
The VALOR study was a global Phase 3 trial enrolling 241 subjects with dermatomyositis across 90 sites. Subjects were randomized 1:1:1 to brepocitinib 30 mg, brepocitinib 15 mg, and placebo. Brepocitinib 30 mg demonstrated statistically significant and clinically meaningful improvement compared to placebo on the primary endpoint of myositis Total Improvement Score (TIS) at Week 52. TIS is a composite endpoint of 6 measures of disease activity. Benefit compared to placebo was seen as early as Week 4 and sustained at every visit thereafter through the end of the one-year double-blind treatment period. Brepocitinib 30 mg also demonstrated statistically significant and clinically meaningful improvement compared to placebo on all nine Key Secondary endpoints evaluated, including measurements of skin disease, muscle disease, and steroid sparing. More than two thirds of brepocitinib 30mg patients achieved a Total Improvement Score of at least 40 (TIS40), twice the minimum clinically important difference. More than half achieved this TIS40 threshold while also achieving steroid dependency of ≤2.5 mg/day.
The VALOR trial enrolled a broad-based DM population including patients with prior history of benign or malignant neoplasm and patients with multiple cardiovascular risk factors. Serious infections in the study were increased in brepocitinib 30 mg compared to placebo; these events resolved with medical management, and brepocitinib treatment was completed in most cases. New or recurrent malignancy, cardiovascular events, and thromboembolic events in the study occurred more frequently in the placebo arm than the brepocitinib 30 mg arm. The brepocitinib safety database across all studies includes over 2,000 patients and subjects and suggests a safety profile similar to approved JAK and TYK2 inhibitors.
About Priovant
Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset is brepocitinib, a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib distinctively suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12, and IL-23—with a single, targeted, once-daily oral therapy. Brepocitinib recently generated positive Phase 3 data in dermatomyositis. The New Drug Application for brepocitinib in dermatomyositis is under review at FDA. Brepocitinib is also being evaluated in a Phase 3 program in non-infectious uveitis and recently generated positive Phase 2 data in cutaneous sarcoidosis, with a Phase 3 study to begin in calendar year 2026. Priovant Therapeutics is a Roivant (Nasdaq: ROIV) company.
Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidate, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidate following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of the filings made by Roivant Sciences Ltd. with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Stephanie Lee, stephanie.lee@priovant.com
FAQ
What is Priovant's PDUFA date for brepocitinib (ROIV) in dermatomyositis?
When does Priovant expect to launch brepocitinib in the U.S. if approved (ROIV)?
What clinical evidence supported the FDA Priority Review for brepocitinib (ROIV)?
Would brepocitinib be the first targeted therapy approved for dermatomyositis (ROIV)?
What does FDA Priority Review mean for brepocitinib's regulatory timeline (ROIV)?
